DOP67 CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signalling pathway
ECCO'20 Vienna
2020
DOP68 Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells via STAT3/IL-6 signal pathway
ECCO'20 Vienna
2020
DOP69 Tofacitinib in ulcerative colitis: Early ‘real-world’ experience from four UK tertiary centres
ECCO'20 Vienna
2020
DOP70 High-dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in inflammatory bowel disease
ECCO'20 Vienna
2020
DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
ECCO'20 Vienna
2020
DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study
ECCO'20 Vienna
2020
DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension
ECCO'20 Vienna
2020
DOP78 Intestinal surgery rates in ulcerative colitis and Crohn’s disease in the era of biologics: A Danish Nationwide Register Study from 2003 to 2016
ECCO'20 Vienna
2020
DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study
ECCO'20 Vienna
2020
DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
ECCO'20 Vienna
2020
DOP82 Macrophages in Crohn’s disease mesentery are predominantly inflammatory and produce calprotectin
ECCO'20 Vienna
2020
DOP83 Intestinal fibrosis in Crohn’s disease patients is marked by up-regulation of innate immune cells and mucosal B cells
ECCO'20 Vienna
2020
DOP84 Crohn’s disease modifies the DNA methylome of human adipose-stem cells, which is only partially re-established in remission
ECCO'20 Vienna
2020